secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001193125-23-135935
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q1 2023 net loss $21.7M; cash $646.6M; DDC IND on track for year-end
--------------------------------------------------------------------------------

- Net loss of $21.7M ($0.10 per share) vs $21.3M ($0.10) in Q1 2022.
- Cash, cash equivalents and marketable securities of $646.6M as of March 31, 2023.
- R&D expenses decreased to $18.8M from $20.7M, primarily due to headcount reduction and NUV-422 program termination.
- Phase 1b combo study of NUV-868 with olaparib/enzalutamide and Phase 1 monotherapy study both enrolling.
- IND submission for first Drug-Drug Conjugate candidate expected by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312523135935/0001193125-23-135935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312523135935/d301084d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-135935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer